Patrick C. DeMartino

Jan 18, 2025 | onlinelibrary.wiley.com | Rena Conti |Patrick C. DeMartino |Jonathan Gruber |Andrew Lo

Cell and gene therapies (CGTs) are highly innovative medicines. There are over two dozen CGTs approved for sale globally, and over the last five years, many clinical trials have progressed toward later stages of development targeting an array of rare genetic disorders and cancers.1, 2 CGTs come with a host of challenges for health care systems, of which perhaps the foremost is affordability.3-5 CGTs are extremely expensive,6 generally in the range of more than $300,000.